NRG ENERGY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NRG ENERGY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.71B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $28.13B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $28.82B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $31.54B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $26.99B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $9.09B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $2.20B | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $3.00B | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $2.47B | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $2.17B | Feb 27, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.35B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $27.75B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $28.26B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $31.49B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $26.78B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $8.69B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $7.99B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $8.15B | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $864.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($202.00M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.22B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.19B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $510.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.44B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $268.00M | Mar 1, 2021 |
| FY2017 | Dec 31, 2017 | ($1.54B) | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $171.00M | Mar 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.42B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $384.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $2.02B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $3.34B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.11B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $209.00M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $540.00M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $320.00M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $221.00M | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $8.00M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $7.00M | Mar 1, 2021 |
| FY2020 | Dec 31, 2018 | $11.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $22.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $48.00M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $154.00M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $88.00M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $84.00M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $68.00M | Feb 27, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.60B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.35B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.09B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.15B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.29B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $810.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $760.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $799.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $836.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.03B | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.91B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.31B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($221.00M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $360.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $493.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.84B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.41B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.38B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.61B | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.91B | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $472.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $598.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $367.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $269.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $230.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $228.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $388.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $254.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $544.00M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.14B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $24.02B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $26.04B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $29.15B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $23.18B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $14.90B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $12.53B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $10.63B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $23.36B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $30.68B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.46B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $21.54B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $23.13B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $25.32B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.58B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $13.22B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.85B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $11.84B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $21.31B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $26.19B | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.01B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $5.08B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.65B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.80B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $579.00M | Feb 23, 2023 |
| FY2020 | Dec 31, 2019 | $579.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $573.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $539.00M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $662.00M | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $820.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.41B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $464.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($1.40B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($1.62B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($6.02B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($6.27B) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($3.79B) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.71B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $966.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $541.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $430.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $250.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.91B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $345.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $563.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $770.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $591.00M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.89B | Feb 26, 2025 |
| FY2024 | Dec 31, 2023 | $10.94B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $8.10B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $8.10B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $8.86B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $6.04B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $6.69B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.49B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $16.70B | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $19.62B | Feb 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 13 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 1 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 13 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 1 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 190.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 198.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 208.13M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | 229.56M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | 243.75M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | 244.23M | Feb 28, 2024 |
| FY2020 | Dec 31, 2019 | 249.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 283.65M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 316.74M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 315.44M | Mar 1, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $411.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $405.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $381.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $332.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $319.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $295.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $32.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $37.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $38.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $76.00M | Feb 28, 2019 |